Inadequate weight loss response (less than 5% body weight reduction after 1216 weeks at therapeutic doses) should trigger reassessment of the treatment plan
Administer Mounjaro once weekly, at the same time and day, for optimal effectiveness and reduced side effects
GLP-1 is an incretin hormone, meaning it helps the body respond to meals
GLP-1 medications may accelerate facial ageing through several mechanisms, including: loss of white adipose (fat) tissue in and beneath the skin changes in the number of fat-derived stem cells altered production and secretion of hormones and metabolic factors These changes affect the skins structure and function, reducing facial muscle mass and enhancing visible signs of ageing

10 Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic 0.5 mg + basal insulin MET 10.7% with Ozempic 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 ADA=American Diabetes Association